Andersons pediatric cardiology 672
Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (60.51 KB, 3 trang )
double-blindplacebo-controlledtrialandits
non-randomisednon-blindextensionphase.
Lancet.2017.
162.SchectmanG,HiattJ.Drugtherapyfor
hypercholesterolemiainpatientswith
cardiovasculardisease:factorslimiting
achievementoflipidgoals.AmJMed.
1996;100(2):197–204.
163.ParizoJ,SarrajuA,KnowlesJW.Novel
therapiesforfamilialhypercholesterolemia.
CurrTreatOptionsCardiovascMed.
2016;18(11):64.
164.SabatineMS,GiuglianoRP,WiviottSD,etal.
Efficacyandsafetyofevolocumabinreducing
lipidsandcardiovascularevents.NEnglJMed.
2015;372(16):1500–1509.
165.RobinsonJG,FarnierM,KrempfM,etal.
Efficacyandsafetyofalirocumabinreducing
lipidsandcardiovascularevents.NEnglJMed.
2015;372(16):1489–1499.
166.BlomDJ,HalaT,BologneseM,etal.A52-week
placebo-controlledtrialofevolocumabin
hyperlipidemia.NEnglJMed.
2014;370(19):1809–1819.
167.SabatineMS,GiuglianoRP,KeechAC,etal.
Evolocumabandclinicaloutcomesinpatients
withcardiovasculardisease.NEnglJMed.
2017;376(18):1713–1722.
168.RaalFJ,SteinEA,DufourR,etal.PCSK9
inhibitionwithevolocumab(AMG145)in
heterozygousfamilialhypercholesterolaemia
(RUTHERFORD-2):arandomised,doubleblind,placebo-controlledtrial.Lancet.
2015;385(9965):331–340.
169.KasteleinJJ,GinsbergHN,LangsletG,etal.
ODYSSEYFHIandFHII:78weekresultswith
alirocumabtreatmentin735patientswith
heterozygousfamilialhypercholesterolaemia.
EurHeartJ.2015;36(43):2996–3003.
170.RaalFJ,HonarpourN,BlomDJ,etal.Inhibition
ofPCSK9withevolocumabinhomozygous
familialhypercholesterolaemia(TESLAPartB):
arandomised,double-blind,placebo-controlled
trial.Lancet.2015;385(9965):341–350.
171.FolsomAR,BurkeGL,BallewC,etal.Relation
ofbodyfatnessanditsdistributionto
cardiovascularriskfactorsinyoungblacksand
whites.Theroleofinsulin.AmJEpidemiol.
1989;130(5):911–924.
172.BurnsTL,MollPP,LauerRM.Increased
familialcardiovascularmortalityinobese
schoolchildren:theMuscatinePonderosity
FamilyStudy.Pediatrics.1992;89(2):262–268.
173.SinaikoAR,DonahueRP,JacobsDRJr,Prineas
RJ.Relationofweightandrateofincreasein
weightduringchildhoodandadolescenceto
bodysize,bloodpressure,fastinginsulin,and
lipidsinyoungadults.TheMinneapolis
Children'sBloodPressureStudy.Circulation.
1999;99(11):1471–1476.
174.MorrisonJA,FriedmanLA,Gray-McGuireC.
Metabolicsyndromeinchildhoodpredictsadult
cardiovasculardisease25yearslater:the
PrincetonLipidResearchClinicsFollow-up
Study.Pediatrics.2007;120(2):340–345.
175.GrundySM,CleemanJI,DanielsSR,etal.
Diagnosisandmanagementofthemetabolic
syndrome:anAmericanHeart
Association/NationalHeart,Lung,andBlood
InstituteScientificStatement.Circulation.
2005;112(17):2735–2752.
176.FordES.Prevalenceofthemetabolicsyndrome
definedbytheInternationalDiabetesFederation
amongadultsintheu.s.DiabetesCare.
2005;28(11):2745–2749.
177.SmoakCG,BurkeGL,WebberLS,etal.
Relationofobesitytoclusteringof
cardiovasculardiseaseriskfactorsinchildren
andyoungadults.TheBogalusaHeartStudy.
AmJEpidemiol.1987;125(3):364–372.
178.GoodmanE,DanielsSR,MeigsJB,DolanLM.
